APA

Czuczman M. S., Leonard J. P., Jung S., Johnson J. L., Hsi E. D., Byrd J. C. & Cheson B. D. (112018). Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Czuczman M S, Leonard J P, Jung S, Johnson J L, Hsi E D, Byrd J C and Cheson B D. 112018. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Czuczman M. S., Leonard J. P., Jung S., Johnson J. L., Hsi E. D., Byrd J. C. and Cheson B. D. (112018). Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Czuczman M S, Leonard J P, Jung S, Johnson J L, Hsi E D, Byrd J C and Cheson B D. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology. 112018.